AURA at a glance
Aura Biosciences, Inc. (AURA, SEC CIK 1501796) filed its latest 10-K annual report on March 30, 2026, a 10-Q quarterly report on August 11, 2026, an 8-K current report on August 11, 2026 and Form 4 insider filings as recently as September 1, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of June 30, 2026, 27 institutional investment managers tracked by SignalX reported holding Aura Biosciences, Inc. (AURA) shares worth $119.1 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 27 funds
- $119.1M · +2 vs prior quarter
- Latest 8-K
- Aug 11, 2026
- Item 2.02 · Item 2.05 · Item 8.01 · Item 5.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- Net losses $79.3 million for six months ended June 30, 2026, with accumulated deficit $559.7 million
- Cash, cash equivalents, and marketable securities expected to fund operations into first half of 2029
- Bel-sar pivotal Phase 3 enrollment complete, but topline data not expected until second half of 2027
- Bel-sar’s drug-device-laser combination creates additional regulatory approval uncertainty
- Bel-sar remains the only product candidate, concentrating development and commercialization risk
AI summary of the AURA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results covered quarter ended June 30, 2026
- Press release issued August 11, 2026
Item 2.05: Costs Associated with Exit or Disposal Activities
- Workforce reduction of approximately 20% as Aura refocuses resources on ocular oncology
- NMIBC program resource allocation to be minimized, signaling reduced strategic emphasis on bladder cancer
Item 8.01: Other Events
- Broad forward-looking disclaimer covering clinical, regulatory, financing, and trial-execution risks
- Phase 3 Special Protocol agreement with FDA remains subject to potential regulatory disagreement
Item EX-99.1: Item EX-99.1
- Phase 3 CoMpass fully enrolled with 108 patients; topline data remain targeted for 2H 2027 under an FDA SPA
- Ocular oncology becomes the core strategy; NMIBC investment reduced despite 81% three-month response and 69% complete response rates
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Susan Abu-Absi appointed COO effective August 10, 2026, adding an operational leader with prior biotech manufacturing and development experience
- COO compensation includes $520,000 base salary, 45% target annual bonus, and approximately 400,000 inducement shares
Item 5.07: Submission of Matters to a Vote of Security Holders
- Stockholders approved increasing authorized common shares from 150 million to 500 million
- Expanded share capacity enables future financing, acquisitions, or strategic transactions, with potential dilution risk
Item EX-99.1: Item EX-99.1
- Jeremy Bender appointed independent director, adding late-stage development, commercialization and oncology transaction expertise
- Appointment strengthens governance as Aura advances bel-sar toward potential regulatory approval
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Board expanded from six to seven directors with Jeremy Bender appointed as an independent Class II director through 2029
- Bender joins Compensation and Nominating and Corporate Governance committees
AI summaries of AURA 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for AURA
Don't miss the next AURA filing
- Alerts as it files. A push when AURA files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut AURA, by share count.
- Ask anything. An AI agent that reads every AURA filing and answers with sources.
AURA alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Hopkins Janet Jill | A | Sep 1, 2026 | 116,150 | - |
| Person Julie | A | Sep 1, 2026 | 107,611 | - |
| Elazzouzi Amy | A | Sep 1, 2026 | 46,460 | - |
| Hopkins Janet Jill | A | Sep 1, 2026 | 58,850 | - |
| Elazzouzi Amy | A | Sep 1, 2026 | 23,540 | - |
| Abu-Absi Susan | A | Sep 1, 2026 | 265,487 | - |
| Kratz Erica | A | Sep 1, 2026 | 100,885 | - |
| Abu-Absi Susan | A | Sep 1, 2026 | 134,513 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Operating Income | -$85.0M | -$96.1M | -$112.8M |
| Net Income | -$76.4M | -$86.9M | -$106.2M |
| Balance Sheet | |||
| Total Assets | $255.1M | $182.5M | $169.4M |
| Equity | - | $152.0M | $136.9M |
| ROE | - | -57.2% | -77.6% |
| Per Share | |||
| EPS | $-1.93 | $-1.75 | $-1.76 |
| Cash Flow | |||
| Operating CF | -$63.8M | -$79.8M | -$84.7M |
| CapEx | $709K | $1.3M | $447K |
Source: XBRL data in Aura Biosciences, Inc. (AURA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate AURA share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 27 | $119.1M |
| Q1 2026 | 25 | $84.8M |
| Q4 2025 | 22 | $57.0M |
| Q3 2025 | 22 | $73.1M |
| Q2 2025 | 23 | $69.1M |
| Q1 2025 | 15 | $38.2M |
| Q4 2024 | 13 | $45.8M |
| Q3 2024 | 11 | $31.2M |
- Vanguard Capital Management LLC+1.86M (+83%)
- BlackRock+1.12M (+31%)
- Vanguard Portfolio Management LLC+480.0K (+123%)
- Goldman Sachs Group+285.9K (+160%)
- State Street Corp+258.3K (+27%)
- Millennium Management−480.2K (-44%)
- T. Rowe Price Group−136.7K (-33%)
- Morgan Stanley−49.3K (-22%)
- Bank of America Corp−38.2K (-30%)
- D.E. Shaw & Co+67.4K
- Prudential Financial+49.0K
Source: 13F-HR filings on SEC EDGAR (aggregated from 158 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
AURA filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 1, 2026 | - | - | - |
| 4 | Sep 1, 2026 | - | - | - |
| 4 | Sep 1, 2026 | - | - | - |
| 4 | Sep 1, 2026 | - | - | - |
| 4 | Sep 1, 2026 | - | - | - |
| SC 13G | Aug 14, 2026 | - | - | |
| 10-Q | Aug 11, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 11, 2026 | - | Analysis | - |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 8-K | Jul 8, 2026 | - | Analysis | - |
| 4 | Jul 8, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jun 16, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 8-K | Jun 11, 2026 | - | Analysis | - |
| 4 | May 19, 2026 | - | - | |
| SC 13G | May 12, 2026 | - | - | |
| 8-K | May 11, 2026 | - | Analysis | |
| 10-Q | May 11, 2026 | Mar 31, 2026 | Analysis | |
| 4 | May 11, 2026 | - | - | |
| 8-K | May 5, 2026 | - | Analysis | - |
| 8-K | May 4, 2026 | - | Analysis | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
AURA SEC filings: frequently asked questions
Which institutions hold AURA stock?
As of June 30, 2026, the largest Aura Biosciences, Inc. (AURA) holders among the 13F filers tracked by SignalX were BlackRock ($33.4 million), Vanguard Capital Management LLC ($29.1 million), Franklin Resources ($14.7 million), State Street Corp ($8.7 million), Vanguard Portfolio Management LLC ($6.2 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What did AURA report in its latest 8-K?
Aura Biosciences, Inc. (AURA) filed an 8-K on August 11, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 2.05 (Costs Associated with Exit or Disposal Activities), Item 8.01 (Other Events) and Item 5.02 (Departure/Appointment of Directors or Principal Officers). Q2 2026 results covered quarter ended June 30, 2026.
What are the latest AURA SEC filings?
Aura Biosciences, Inc. (AURA) filed its latest 10-K annual report on March 30, 2026, a 10-Q quarterly report on August 11, 2026, an 8-K current report on August 11, 2026 and a Form 4 insider filing on September 1, 2026.
What is AURA's SEC CIK number?
Aura Biosciences, Inc. (AURA)'s SEC Central Index Key (CIK) is 1501796. EDGAR lists every AURA filing under that number.
Ask anything about AURA
The research agent reads AURA's filings, financials, insider trades and 13F holders, then answers with sources.